Evidence map›Paper›PMID 37192099›Full record

ReviewBiochemistry2023

Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.

Eugene V Koonin, Jonathan S Gootenberg, Omar O Abudayyeh

Open access · greenAbstract readReview
In one paragraph

Review in Biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Machine Learning for CRISPR-Based Diagnostics.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Structural visualization of the molecular evolution of CRISPR-Cas9.Nature structural & molecular biology · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Mutational scanning of TnpB reveals latent activity for genome editing.bioRxiv : the preprint server for biology · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Amplification-free, OR-gated CRISPR-Cascade reaction for pathogen detection in blood samples.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Eugene V KooninNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, United States.ORCID 0000-0003-3943-8299
Jonathan S GootenbergMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Omar O AbudayyehMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
McGovern Institute for Brain Research · USNational Institutes of Health · US

Funding

Comparative Analysis Of Completely Sequenced GenomesZIALM000073 · NLM · NATIONAL LIBRARY OF MEDICINE · PI KOONIN, EUGENE V · 2009 to 2025
$43.1M
Programmable gene integration and cell engineering with CRISPR-directed integrasesR01EB031957 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2024
$2.4M
Systematic discovery, characterization, and design of novel genome editing and delivery tools using a high-throughput metagenomic screening pipelineR21AI149694 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2020 to 2021
$414k
RNA targeting tools with novel specific RNA-guided RNA-targeting CRISPR effectorsR56HG011857 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2021
$363k
NHGRI NIH HHS R56 HG011857NIAID NIH HHS R21 AI149694NIBIB NIH HHS R01 EB031957
6 · The paper itself

Abstract

CRISPR systems mediate adaptive immunity in bacteria and archaea through diverse effector mechanisms and have been repurposed for versatile applications in therapeutics and diagnostics thanks to their facile reprogramming with RNA guides. RNA-guided CRISPR-Cas targeting and interference are mediated by effectors that are either components of multisubunit complexes in class 1 systems or multidomain single-effector proteins in class 2. The compact class 2 CRISPR systems have been broadly adopted for multiple applications, especially genome editing, leading to a transformation of the molecular biology and biotechnology toolkit. The diversity of class 2 effector enzymes, initially limited to the Cas9 nuclease, was substantially expanded via computational genome and metagenome mining to include numerous variants of Cas12 and Cas13, providing substrates for the development of versatile, orthogonal molecular tools. Characterization of these diverse CRISPR effectors uncovered many new features, including distinct protospacer adjacent motifs (PAMs) that expand the targeting space, improved editing specificity, RNA rather than DNA targeting, smaller crRNAs, staggered and blunt end cuts, miniature enzymes, promiscuous RNA and DNA cleavage, etc. These unique properties enabled multiple applications, such as harnessing the promiscuous RNase activity of the type VI effector, Cas13, for supersensitive nucleic acid detection. class 1 CRISPR systems have been adopted for genome editing, as well, despite the challenge of expressing and delivering the multiprotein class 1 effectors. The rich diversity of CRISPR enzymes led to rapid maturation of the genome editing toolbox, with capabilities such as gene knockout, base editing, prime editing, gene insertion, DNA imaging, epigenetic modulation, transcriptional modulation, and RNA editing. Combined with rational design and engineering of the effector proteins and associated RNAs, the natural diversity of CRISPR and related bacterial RNA-guided systems provides a vast resource for expanding the repertoire of tools for molecular biology and biotechnology.

Indexed as

CRISPR-Cas SystemsGene EditingBacteriaDNARNA, BacterialDNARNA, Bacterial

Identifiers

PMID37192099
PMCPMC10734277
OpenAlexW4376648037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.